{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:43:21Z","timestamp":1793479401877,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is a chronic immuno-inflammatory disease whose outcomes can vary greatly from one patient to another. One of the main prognostic factors is the presence of serum autoantibodies, such as rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA). Indeed, when seropositive, patients with RA are at higher risk of radiographic progression, disability, and increased mortality. Moreover, while the introduction of the 2010 American College of Rheumatology\/European Alliance of Associations for Rheumatology (ACR\/EULAR) classification criteria has allowed for an earlier diagnosis, studies on large early arthritis cohorts have also shown that these criteria are less capable of identifying seronegative patients, who are therefore at a higher risk of being diagnosed and treated late. In light of these, the major randomized controlled trials have mostly enrolled patients with autoantibody-positive disease. However, in recent years, it became evident that the two serotypes of RA differ significantly from many points of view. Alongside this, a greater understanding of the disease pathogenesis, particularly the presence of antibodies in patients\u2019 serum even before the onset of arthritis, has generated significant interest in exploring whether the disease could be prevented by treating patients in the pre-arthritis phases. Once again, emerging trials predominantly enroll subjects positive for RA autoantibodies, potentially overlooking seronegative individuals with arthralgia-at-risk.<\/jats:p>","DOI":"10.1007\/s10067-024-07187-w","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T22:01:44Z","timestamp":1729893704000},"page":"515-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Are seronegative patients with rheumatoid arthritis and clinically suspect arthralgia properly represented in randomized clinical trials?"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-5057","authenticated-orcid":false,"given":"Bernardo","family":"D\u2019Onofrio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"13","key":"7187_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA - J Am Med Assoc 320(13):1360\u20131372","journal-title":"JAMA - J Am Med Assoc"},{"issue":"9","key":"7187_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1003296","volume":"17","author":"XME Matthijssen","year":"2020","unstructured":"Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-Van Mil AHM (2020) Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands. PLoS Med 17(9):1\u201318","journal-title":"PLoS Med"},{"issue":"2","key":"7187_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2017.04.009","volume":"47","author":"DM Boeters","year":"2017","unstructured":"Boeters DM, Gaujoux-Viala C, Constantin A, van der Helm-van Mil AHM (2017) The 2010 ACR\/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: results from the Leiden-EAC and ESPOIR cohorts. Semin Arthritis Rheum 47(2):170\u2013174","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"7187_CR4","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(23)00242-4","volume":"5","author":"S Bugatti","year":"2023","unstructured":"Bugatti S, De Stefano L, Gandolfo S, Ciccia F, Montecucco C (2023) Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist. Lancet Rheumatol 5(12):e743\u2013e755","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"7187_CR5","doi-asserted-by":"publisher","first-page":"e003611","DOI":"10.1136\/rmdopen-2023-003611","volume":"9","author":"A Sepriano","year":"2023","unstructured":"Sepriano A, van Dijk B, Ramiro S, van der Helm-van Mil A, Combe B, van Schaardenburg D et al (2023) Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts. RMD Open 9(4):e003611","journal-title":"RMD Open"},{"key":"7187_CR6","doi-asserted-by":"crossref","unstructured":"Ruscitti P, Allanore Y, Baldini C, Barilaro G, Bocci EB, Bearzi P et al (2024) Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts\u2019 consensus. Autoimmun Rev 23(7\u20138), 103581","DOI":"10.1016\/j.autrev.2024.103581"},{"issue":"5","key":"7187_CR7","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/rheumatology\/kead378","volume":"63","author":"L De Stefano","year":"2024","unstructured":"De Stefano L, Bugatti S, Mazzucchelli I, Rossi S, Xoxi B, BozzallaCassione E et al (2024) Synovial and serum B cell signature of autoantibody-negative rheumatoid arthritis vs autoantibody-positive rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford) 63(5):1322\u20131331","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"7187_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/cells13090743","volume":"13","author":"J Perera","year":"2024","unstructured":"Perera J, Delrosso CA, Nerviani A, Pitzalis C (2024) Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: a literature review. Cells 13(9):743","journal-title":"Cells"},{"issue":"1","key":"7187_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13075-019-1898-7","volume":"21","author":"S Alivernini","year":"2019","unstructured":"Alivernini S, Bruno D, Tolusso B, Bui L, Petricca L, Gigante MR et al (2019) Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor\/anti-citrulline antibody-negative rheumatoid arthritis. Arthritis Res Ther 21(1):116","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"7187_CR10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB et al (2021) Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 80(7):848\u2013858","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7187_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","volume":"80","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J et al (2021) Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis 80(6):727\u2013738","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7187_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg J-E, Mozaffarian N, Bartok B, Matzkies F et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322(4):315\u2013325","journal-title":"JAMA"},{"issue":"6","key":"7187_CR13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","volume":"76","author":"R Westhovens","year":"2017","unstructured":"Westhovens R, Taylor PC, Alten R, Pavlova D, Enr\u00edquez-Sosa F, Mazur M et al (2017) Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76(6):998\u20131008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7187_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","volume":"76","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M et al (2017) Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76(6):1009\u20131019","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"7187_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383(16):1511\u20131521","journal-title":"N Engl J Med"},{"key":"7187_CR16","doi-asserted-by":"crossref","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed M-EF, Chen S et al (2020) Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol (Hoboken, NJ) 72(10):1607\u201320","DOI":"10.1002\/art.41384"},{"issue":"10188","key":"7187_CR17","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393(10188):2303\u20132311","journal-title":"Lancet"},{"issue":"11","key":"7187_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song I, Mysler E, Bessette L, Peterfy C et al (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71(11):1788\u20131800","journal-title":"Arthritis Rheumatol"},{"issue":"10139","key":"7187_CR19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y et al (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391(10139):2503\u20132512","journal-title":"Lancet"},{"issue":"10139","key":"7187_CR20","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391(10139):2513\u20132524","journal-title":"Lancet"},{"issue":"10093","key":"7187_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet (London, England) 390(10093):457\u2013468","journal-title":"Lancet (London, England)"},{"issue":"7","key":"7187_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"3","key":"7187_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69(3):506\u2013517","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7187_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen Y-C, Greenwald M, Drescher E, Liu J et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88\u201395","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"7187_CR25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"12","key":"7187_CR26","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/annrheumdis-2013-203742","volume":"73","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S et al (2014) Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo cont. Ann Rheum Dis 73(12):2152\u20132159","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"7187_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M \u00d8stergaard","year":"2023","unstructured":"\u00d8stergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordstr\u00f6m DC et al (2023) Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis 82(10):1286\u20131295","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7187_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3109\/14397595.2013.843764","volume":"24","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K et al (2014) Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol 24(4):552\u2013560","journal-title":"Mod Rheumatol"},{"issue":"5","key":"7187_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","volume":"74","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR et al (2015) Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 74(5):843\u2013850","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7187_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/14397595.2013.864224","volume":"24","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K et al (2014) Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol 24(5):715\u2013724","journal-title":"Mod Rheumatol"},{"issue":"10271","key":"7187_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F et al (2021) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet (London, England) 397(10271):305\u2013317","journal-title":"Lancet (London, England)"},{"issue":"6","key":"7187_CR32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A et al (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75(6):1081\u20131091","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7187_CR33","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/acr.22384","volume":"66","author":"A Kivitz","year":"2014","unstructured":"Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC et al (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(11):1653\u20131661","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"7187_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","volume":"387","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL et al (2022) Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 387(8):715\u2013726","journal-title":"N Engl J Med"},{"issue":"4","key":"7187_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","volume":"81","author":"E Nasonov","year":"2022","unstructured":"Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG et al (2022) Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis 81(4):469\u2013479","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7187_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NMH et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76(5):840\u2013847","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7187_CR37","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TWJ Huizinga","year":"2014","unstructured":"Huizinga TWJ, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S et al (2014) Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann Rheum Dis 73(9):1626\u20131634","journal-title":"Ann Rheum Dis"},{"key":"7187_CR38","doi-asserted-by":"crossref","unstructured":"Van der Helm\u2013van Mil AHM (2023) Preventive interventions in individuals at risk for rheumatoid arthritis: state of the art and perspectives. Jt Bone Spine 90(4):105543.","DOI":"10.1016\/j.jbspin.2023.105543"},{"key":"7187_CR39","doi-asserted-by":"crossref","unstructured":"van Steenbergen HW, da Silva JAP, Huizinga TWJ, van der Helm-van Mil AHM (2018) Preventing progression from arthralgia to arthritis: targeting the right patients. Nat Rev Rheumatol 14(1):32\u201341. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29118439","DOI":"10.1038\/nrrheum.2017.185"},{"issue":"2","key":"7187_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46(2):183\u2013196","journal-title":"Immunity"},{"issue":"10429","key":"7187_CR41","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","volume":"403","author":"AP Cope","year":"2024","unstructured":"Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S et al (2024) Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403(10429):838\u2013849","journal-title":"Lancet"},{"issue":"10429","key":"7187_CR42","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V et al (2024) Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403(10429):850\u2013859","journal-title":"Lancet"},{"issue":"2","key":"7187_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","volume":"78","author":"DM Gerlag","year":"2019","unstructured":"Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF et al (2019) Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis 78(2):179\u2013185","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7187_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2008.105767","volume":"69","author":"WH Bos","year":"2010","unstructured":"Bos WH, Dijkmans BAC, Boers M, van de Stadt RJ, van Schaardenburg D (2010) Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis 69(3):571\u2013574","journal-title":"Ann Rheum Dis"},{"key":"7187_CR45","unstructured":"Holers V. M DK (2022) Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial. In: Hydroxychloroquine does not prevent the future development of rheumatoid arthritis in a population with baseline high levels of antibodies to citrullinated protein antigens and absence of inflammatory arthritis: interim analysis of the StopRA trial."},{"issue":"1","key":"7187_CR46","doi-asserted-by":"publisher","first-page":"e001591","DOI":"10.1136\/rmdopen-2021-001591","volume":"7","author":"L van Boheemen","year":"2021","unstructured":"van Boheemen L, Turk S, van Beers-Tas M, Bos W, Marsman D, Griep EN et al (2021) Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to prevent rheumatoid arthritis (STAPRA) trial. RMD open 7(1):e001591","journal-title":"RMD open"},{"issue":"1","key":"7187_CR47","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1186\/s13063-021-05682-y","volume":"22","author":"W Walrabenstein","year":"2021","unstructured":"Walrabenstein W, van der Leeden M, Weijs P, van Middendorp H, Wagenaar C, van Dongen JM et al (2021) The effect of a multidisciplinary lifestyle program for patients with rheumatoid arthritis, an increased risk for rheumatoid arthritis or with metabolic syndrome-associated osteoarthritis: the \u201cplants for joints\u201d randomized controlled trial protocol. Trials 22(1):715","journal-title":"Trials"},{"issue":"10348","key":"7187_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","volume":"400","author":"DI Krijbolder","year":"2022","unstructured":"Krijbolder DI, Verstappen M, van Dijk BT, Dakkak YJ, Burgers LE, Boer AC et al (2022) Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet 400(10348):283\u2013294","journal-title":"Lancet"},{"key":"7187_CR49","doi-asserted-by":"crossref","unstructured":"Dumoulin QA, Krijbolder DI, Visser K, Lard LR, Van der Helm \u2013 van Mil AHM (2024) POS0061 interception of the development of rheumatoid arthritis by a 1-year course of methotrexate in acpa-negative arthralgia patients at increased risk for rheumatoid arthritis: 4 year results of the TREAT EARLIER trial. In: Scientific abstracts . BMJ Publishing Group Ltd and European League Against Rheumatism p. 454.2\u2013455","DOI":"10.1136\/annrheumdis-2024-eular.1995"},{"issue":"3","key":"7187_CR50","first-page":"554","volume":"41","author":"L De Stefano","year":"2023","unstructured":"De Stefano L, D\u2019Onofrio B, Gandolfo S, BozzallaCassione E, Mauro D, Manzo A et al (2023) Seronegative rheumatoid arthritis: one year in review 2023. Clin Exp Rheumatol 41(3):554\u2013564","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"7187_CR51","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/S2665-9913(23)00129-7","volume":"5","author":"BT van Dijk","year":"2023","unstructured":"van Dijk BT, Wisse LJ, van Steenbergen HW, Reijnierse M, Khidir SJH, DeRuiter MC et al (2023) Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study. Lancet Rheumatol 5(7):e401\u2013e412","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"7187_CR52","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.42260","volume":"74","author":"MJ Loza","year":"2022","unstructured":"Loza MJ, Nagpal S, Cole S, Laird RM, Alcala A, Rao NL et al (2022) Serologic biomarkers of progression toward diagnosis of rheumatoid arthritis in active component military personnel. Arthritis Rheumatol 74(11):1766\u20131775","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"7187_CR53","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/annrheumdis-2022-222436","volume":"81","author":"S Bugatti","year":"2022","unstructured":"Bugatti S, De Stefano L, D\u2019Onofrio B, Nicrosini A, Mauric E, di Lernia M et al (2022) Inflammatory correlates of the patient global assessment of disease activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. Ann Rheum Dis 81(9):1206\u20131213","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7187_CR54","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/annrheumdis-2012-201456","volume":"72","author":"E Gremese","year":"2013","unstructured":"Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 72(6):858\u2013862","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7187_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2017.04.009","volume":"47","author":"DM Boeters","year":"2017","unstructured":"Boeters DM, Gaujoux-Viala C, Constantin A, van der Helm-van Mil AH (2017) The 2010 ACR\/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: results from the Leiden-EAC and ESPOIR cohorts. Semin Arthritis Rheum 47(2):170\u2013174","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"7187_CR56","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/annrheumdis-2022-222264","volume":"81","author":"L De Stefano","year":"2022","unstructured":"De Stefano L, D\u2019Onofrio B, Sakellariou G, Manzo A, Montecucco C, Bugatti S (2022) Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic. Ann Rheum Dis 81(9):1331\u20131332","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7187_CR57","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/rheumatology\/keae044","volume":"63","author":"SJH Khidir","year":"2024","unstructured":"Khidir SJH, Krijbolder DI, Glas HK, van Mulligen E, van der Helm-van Mil AHM (2024) Patient burden and joint inflammation during development of RA from arthralgia: is it similar in ACPA-positive and ACPA-negative disease? Rheumatology 63(9):2336\u20132344","journal-title":"Rheumatology"},{"issue":"9","key":"7187_CR58","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1093\/rheumatology\/keae106","volume":"63","author":"M Doumen","year":"2024","unstructured":"Doumen M, Westhovens R, Verschueren P (2024) Individuals with ACPA-negative clinically suspect arthralgia experience more symptom burden: is seronegative disease truly less severe? Rheumatology 63(9):2323\u20132324","journal-title":"Rheumatology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07187-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07187-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07187-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T08:50:54Z","timestamp":1736758254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07187-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7187"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07187-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}